Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products

Recombinant tissue plasminogen activator (international nonproprietary name — alteplase) which was developed by «GENERIUM» (Russia) and received a marketing authorisation in Russia is completely analogous to Actilyse® which is used to treat medical conditions accompanied by thrombosis, such as acute myocardial infarction, pulmonary embolism, and ischemic stroke. The aim of the study was to carry out a comprehensive comparison of physico-chemical and biological properties of Revelyse® and the reference product Actilyse® in order to assess their biosimilarity. Materials and Methods: comparative peptide mapping and determination of comparability of chromatographic profiles of tryptic hydrolysates was performed using RP-HPLC and massspectrometry; the molecular weight distribution was determined by mass-spectrometry and polyacrylamide gel electrophoresis (Laemmli method). The purity and homogeneity of products as well as the content of related impurities (oligomers and fragments) were determined using gel filtration; N-glycosylation profile was analysed by hydrophilic HPLC, total sialic acid was quantified by the Svennerholm resorcinol method. Protein binding to fibrin and human fibrinogen was assessed by surface plasmon resonance, and the specific activity was compared by fibrin clot lysis. Results: the research demonstrated a complete overlap of the products’ peptide maps, which indicates the identity of аlteplase amino acid sequences in the two medicines being compared. The authors of the study also determined the molecular weight and the content of the intact single-stranded form of the protein, and quantified post-translational modifications, the content of sialic acids and neutral sugars. The analysis of the N-glycosylation profile revealed insignificant differences in the percentage of multiantenna complex glycans. The specificity of alteplase was evaluated by analysing the formation of protein complexes with natural alteplase ligands – fibrin and plasminogen activator inhibitor-1, but no significant differences were found. The comparison of specific activation of plasminogen fibrinolytic activity was performed based on the results of the assay analysing the fibrin clot lysis rate, and it demonstrated comparability of Revelyse® and Actilyse®. Conclusions: comparative experimental studies have shown no differences in the structure, charge distribution heterogeneity, impurities content, and specific activity of alteplase as a component of Revelyse® and the reference product Actilyse®, which leads to the conclusion that they are similar in terms of physicochemical and biological properties.

1. Guzzetta AW, Basa LJ, Hancock WS, Keyt BA, Bennett WF. Identification of carbohydrate structures in glycoprotein peptide maps by the use of LC/MS with selected ion extraction with special reference to tissue plasminogen activator and a glycosylation variant produced by site directed mutagenesis. Anal Chem. 1993;65(21):2953–62.

2. Spellman MW, Basa LJ, Leonard CK, Chakel JA, O’ConnorJV, Wilson S, van Halbeek H. Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells. J Biol Chem. 1989;264(24):14100–11.

3. Harris RJ, Leonard CK, Guzzetta AW, Spellman MW. Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain. Biochemistry. 1991;30(9):2311–4.

4. Parekh RB, Dwek RA, Thomas JR, Opdenakker G, Rademacher TW, Wittwer AJ, et al. Cell-type-specific and site-specific N-glycosylation of type I and type II human tissue plasminogen activator. Biochemistry. 1989;28(19):7644–62.

5. Wittwer AJ, Howard SC, Carr LS, Harakas NK, Feder J, Parekh RB, et al. Effects of N-glycosylation on in vitro activity of Bowes melanoma and human colon fibroblast derived tissue plasminogen activator. Biochemistry. 1989;28(19):7662–9.

6. Berg DT, Burck PJ, Berg DH, Grinnell BW. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties. Blood. 1993;81(5):1312–22.

7. Cole ES, Nichols EH, Poisson L, Harnois ML, Livingston DJ. In vivo clearance of tissue plasminogen activator: The complex role of sites of glycosylation and level of sialylation. Fibrinilysis. 1993;7(1):15–22. https://doi.org/10.1016/0268-9499(93)90050-6

8. Chloupek RC, Harris RJ, Leonard CK, Keck RG, Keyt BA, Spellman MW, et al. Study of the primary structure of recombinant tissue plasminogen activator by reversedphase high-performance liquid chromatographic tryptic mapping. J Chromatogr. 1989;463(2):375–96.

9. Kim PY, Tieu LD, Stafford AR, Fredenburgh JC, Weitz JI. A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J Biol Chem. 2012;287(7):4652–61. https://doi.org/10.1074/jbc.M111.317719

10. Björquist P, Brohlin M, Ehnebom J, Ericsson M, Kristansen C, Pohl G, Deinum J. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochim Biophys Acta. 1994;1209(2):191–202.